HC Wainwright Forecasts Increased Earnings for Vor Biopharma

Vor Biopharma Inc. (NASDAQ:VOR) – Equities researchers at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Vor Biopharma in a research report issued to clients and investors on Tuesday, April 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.88) per share for the quarter, up from their prior forecast of ($1.65). HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. HC Wainwright also issued estimates for Vor Biopharma’s Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at $4.16 EPS.

Other analysts also recently issued reports about the company. Wedbush increased their target price on Vor Biopharma to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Citigroup initiated coverage on Vor Biopharma in a research note on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group initiated coverage on Vor Biopharma in a research report on Monday, March 30th. They set a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. decreased their price target on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.56.

Vor Biopharma Trading Up 10.8%

Vor Biopharma stock opened at $16.59 on Friday. The business’s fifty day simple moving average is $14.72 and its two-hundred day simple moving average is $16.51. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80. The company has a market capitalization of $810.42 million, a price-to-earnings ratio of -0.04 and a beta of 1.92.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 53,644 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $16.01, for a total value of $858,840.44. Following the completion of the transaction, the director owned 3,197,619 shares of the company’s stock, valued at $51,193,880.19. The trade was a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 2,207,379 shares of company stock valued at $36,632,973 in the last ninety days. 0.45% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently made changes to their positions in VOR. RA Capital Management L.P. increased its position in shares of Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after purchasing an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. grew its position in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after acquiring an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in Vor Biopharma in the 4th quarter worth about $13,080,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Key Vor Biopharma News

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: HC Wainwright materially raised forward EPS estimates (Q1–Q4 2026 and FY2026–2029), cutting projected losses for 2026–2028 and now forecasting FY2029 EPS of $4.16; the firm keeps a “Buy” rating and $31 price target — this reduces near‑term downside in forecasts and signals brighter long‑term expectations. HC Wainwright research note
• Neutral Sentiment: Broader Wall Street coverage remains mixed-to-positive: multiple firms have buy/overweight ratings while several maintain holds; the MarketBeat consensus target remains well above the current price, implying analyst upside but with dispersion in conviction. Analyst coverage summary
• Neutral Sentiment: Institutional ownership is high (reported ~97% held by institutions) and some new stakes were disclosed recently; that concentration can amplify moves but also means flow changes (in or out) matter more than usual. Institutional holdings update
• Negative Sentiment: Ra Capital Management, L.P. (a director-level holder) has been an active seller in April, unloading multiple tranches (including >500k shares on Apr 13 and additional sales on Apr 2–15), trimming its position materially — this large insider selling increases supply and is likely weighing on sentiment. SEC Form 4 — Ra Capital sales Coverage of Ra Capital sales

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).